How AI and a Global Pandemic led to a $175M Investment: Ardis Kadiu’s Element451 Story
From Legislation to Implementation: Understanding Section 1202 Changes — Troutman Pepper Locke Podcast
No Password Required: From Heavy Metal to the Front Lines of Cyber Innovation
12 O’Clock High: Navigating Life’s Challenges: A Journey from Military Service to Mental Health Advocacy with Nick Padlo
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 247: Reimagining Cell Therapy for Solid Tumors with Ming-Wei Chen and Fangheng Zhou of RephImmune
Regulatory Ramblings: Episode 75 - Rethinking Hong Kong’s Startup Ecosystem and Its Legal Foundations with Syed Musheer Ahmed, Joshua Chu, and David Cameron
Money-Saving Licensing Tips for Startups
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 242: Business Planning in Healthcare & Life Sciences with Jennifer McEwen of Maynard Nexsen
From Banks to FinTech: The Evolution of Small Business Lending — The Consumer Finance Podcast
How Startups Can Comply With Ever-Changing Privacy Laws
The Future of Supply Chains: Chris Andrassy on Using AI to Predict & Prevent Disruptions
How IP Can Fuel Your Startup's Growth
Strategies for Startups at Foundation
A Guide to SEP: Standard Essential Patents for Tech Startups
Innovation in Compliance: Visionary Leadership with Jackson Calame
The Entrepreneur's Journey with Kass and Mike Lazerow
AGG Talks: Women in Tech Law Podcast - Episode 6: Navigating the Legal Landscape of Venture Capital: Key Considerations for Startups
Creating Impact Through Innovation: Brandon Kashani on Leading Mission-Driven Startups
A una acción de retener talento
AGG Talks: Cross-Border Business Podcast - Episode 25: Venture Capital Trends and Fundraising Strategies for Foreign Startups Expanding to the U.S.
Though largely absent from mainstream news, proposed reforms to patent law are poised to affect everything from biotech startups to major pharmaceutical R&D programs. Specifically, there are four ongoing bipartisan efforts to...more
This week, hosts Matthew and Heather welcome back James Chappell, President and CEO of SCbio, to discuss the organization’s new program, SCbioDrive, an accelerator program for emerging life sciences companies. The group...more
Wilson Sonsini’s 2020 Technology and Life Sciences IPO Report presents analysis and data related to the pricing of 123 initial public offerings completed by U.S.-based technology and life sciences companies between January 1...more
Emerging companies have historically been backed by venture capital funds, but as Europe’s startup scene matures, involvement by more traditional private equity investors is growing, particularly in the tech, consumer, and...more
US IPO volume has declined by almost a quarter year-over-year, according to EY’s recent Global IPO trends report. To date, $44.5 billion in proceeds have been raised in 127 IPOs, 23% less than at the end of Q3 2018. The...more
Access to capital is critical for life sciences companies. Securing funding can be a lengthy and complex process compounded by the need to plan for various exit transaction scenarios. Register now for this one-hour,...more
In our 2018 year-end review of life sciences and tech IPOs, we noted that life sciences offerings totaled 67 raising an average of $133 million while there were 45 technology deals raising an average of more than $380...more
As a pioneer in DNA synthesis with several patents to her name, Dr. Emily Leproust could have enjoyed a distinguished career without ever leaving the lab. Instead she founded (and just took public) a company that promises to...more
More than ever, life sciences companies are going public to raise capital for future growth. In fact, U.S. equity financing in life sciences skyrocketed to a record $7 billion in 2018—a 69 percent jump over the year before. ...more
Fenwick’s Sixth Annual Digital Health Investor Summit started on an upbeat note with Rock Health’s Megan Zweig sharing the venture fund’s mid-year funding report. After the uncertainty brought by the 2016 presidential...more
One of the biggest contributors to a lack of corporate diversity is the size of a company. And the problems are often traceable to the company’s leanest, earliest days. One of my key messages to clients is that it’s never too...more
This report has been developed as a resource for our clients and friends interested in understanding recent IPO activity of technology and life sciences companies. This information comprises a number of graphs and charts...more
As we reported in January 2015, 2014 was a banner year for venture capital on all fronts, from fundraising, to investment and exits – save, however, for the small drop in the number of deals versus the largest aggregate...more